Polio endgame: the global switch from tOPV to bOPV.
作者： Julie Garon , Katherine Seib , Walter A. Orenstein , Alejandro Ramirez Gonzalez , Diana Chang Blanc
DOI: 10.1586/14760584.2016.1140041
关键词:
摘要: Globally, polio cases have reached an all-time low, and type 2 poliovirus (one of three) is eradicated. Oral vaccine (OPV) has been the primary tool, however, in rare cases, OPV induces paralysis. In 2013, World Health Assembly endorsed phased withdrawal introduction inactivated (IPV) into childhood routine immunization schedules. Type will be withdrawn through a globally synchronized "switch" from trivalent (all three types) to bivalent (types 1 3). The switch happen 155 OPV-using countries between April 17(th) May 1(st), 2016. Planned activities reduce outbreak risks post-switch include following: tOPV campaigns increase immunity prior switch, monovalent OPV2 stockpiling respond outbreaks should they occur, containment both wild viruses, enhanced acute flaccid paralysis (AFP) environmental surveillance, response protocols, ensured access IPV OPV.
sci-hub.se 参考文章(46)
Harish Nair, Indrajit Hazarika, Ashok Patwari, A roller-coaster ride: introduction of pentavalent vaccine in India. Journal of Global Health. ,vol. 1, pp. 32- 35 ,(2011)
John Tj, Vashishtha Vm, Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status Indian Journal of Medical Research. ,vol. 137, pp. 881- 894 ,(2013)
R. W. Sutter, W. R. Dowdle, D. J. Wood, Stopping poliovirus vaccination after eradication: issues and challenges Bulletin of The World Health Organization. ,vol. 78, pp. 347- 357 ,(2000) , 10.1590/S0042-96862000000300010
Radboud J. Duintjer Tebbens, Kimberly M. Thompson, Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs BMC Infectious Diseases. ,vol. 15, pp. 390- 390 ,(2015) , 10.1186/S12879-015-1114-6
Kimberly M. Thompson, Radboud J. Duintjer Tebbens, Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes BMC Infectious Diseases. ,vol. 15, pp. 374- 374 ,(2015) , 10.1186/S12879-015-1113-7
Sarmad Manya, Javaria Qazi, From Pakistan a line of hope for ‘The Polio Eradication and Endgame Strategic Plan 2013–2018’ Infectious diseases. ,vol. 48, pp. 167- 168 ,(2016) , 10.3109/23744235.2015.1092050
Thomas R Hird, Nicholas C Grassly, None, Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge PLOS Pathogens. ,vol. 8, ,(2012) , 10.1371/JOURNAL.PPAT.1002599
Yash Paul, OPV cannot eradicate polio from India: do we need any further evidence? Vaccine. ,vol. 26, pp. 2058- 2061 ,(2008) , 10.1016/J.VACCINE.2008.02.054
Li Lu, Xiaomei Li, Herun Zhang, Donglei Liu, Zhujiazi Zhang, Haihong Wang, Fang Liu, Zhaoqi Ning, Juan Li, Xinghuo Pang, Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infants Vaccine. ,vol. 33, pp. 4653- 4658 ,(2015) , 10.1016/J.VACCINE.2014.08.091
M. A. McKinlay, M. S. Collett, J. R. Hincks, M. S. Oberste, M. A. Pallansch, H. Okayasu, R. W. Sutter, J. F. Modlin, W. R. Dowdle, Progress in the Development of Poliovirus Antiviral Agents and Their Essential Role in Reducing Risks That Threaten Eradication The Journal of Infectious Diseases. ,vol. 210, ,(2014) , 10.1093/INFDIS/JIU043